0001179110-14-001425.txt : 20140127 0001179110-14-001425.hdr.sgml : 20140127 20140127213956 ACCESSION NUMBER: 0001179110-14-001425 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140124 FILED AS OF DATE: 20140127 DATE AS OF CHANGE: 20140127 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Onconova Therapeutics, Inc. CENTRAL INDEX KEY: 0001130598 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 375 PHEASANT RUN CITY: NEWTOWN STATE: PA ZIP: 18940 BUSINESS PHONE: 267-759-3681 MAIL ADDRESS: STREET 1: 375 PHEASANT RUN CITY: NEWTOWN STATE: PA ZIP: 18940 FORMER COMPANY: FORMER CONFORMED NAME: ONCONOVA THERAPEUTICS, INC. DATE OF NAME CHANGE: 20090526 FORMER COMPANY: FORMER CONFORMED NAME: ONCONOVA THERAPEUTICS INC DATE OF NAME CHANGE: 20001226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Michael & Jane Hoffman 2013 Descendants CENTRAL INDEX KEY: 0001581996 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36020 FILM NUMBER: 14550402 BUSINESS ADDRESS: STREET 1: 375 PHEASANT RUN CITY: NEWTOWN STATE: PA ZIP: 18940 BUSINESS PHONE: 267-759-3690 MAIL ADDRESS: STREET 1: 375 PHEASANT RUN CITY: NEWTOWN STATE: PA ZIP: 18940 4 1 edgar.xml FORM 4 - X0306 4 2014-01-24 0 0001130598 Onconova Therapeutics, Inc. ONTX 0001581996 Michael & Jane Hoffman 2013 Descendants 712 FIFTH AVENUE, 36TH FLOOR NEW YORK NY 10019 0 0 1 0 Common Stock 2014-01-24 4 P 0 31706 11.96 A 4349206 D Common Stock 2014-01-27 4 P 0 25589 11.86 A 4374795 D The price reported in Column 4 is a weighted average price. These shares were purchased, pursuant to a 10b5-1 plan, in multiple transactions at prices ranging from $11.91 to $12.00,inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased, pursuant to a 10b5-1 plan, in multiple transactions at prices ranging from $11.51 to $12.00,inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4. /s/ By Ajay Bansal as attorney-in-fact 2014-01-27